Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Siringo

Showing results (101-110 of 116) with videos related to

Pageof 12
Sort By:
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 27, 2018
The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseasesFabio Salvatore Macaluso, Rosalba Orlando, Walter Fries, et al.
Retina (Philadelphia, Pa.)|December 29, 2017
COLORADO AGE-RELATED MACULAR DEGENERATION REGISTRY: Design and Clinical Risk Factors of the CohortAnne M Lynch, Jennifer L Patnaik, Jennifer N Cathcart, et al.
United European Gastroenterology Journal|August 11, 2020
Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre studyFabio Salvatore Macaluso, Walter Fries, Sara Renna, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 16, 2018
A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysisSara Renna, Filippo Mocciaro, Marco Ventimiglia, et al.
Drugs & Aging|February 5, 2020
Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)Serena Porcari, Anna Viola, Ambrogio Orlando, et al.
Nature|March 23, 2010
Intense star formation within resolved compact regions in a galaxy at z = 2.3A M Swinbank, I Smail, S Longmore, et al.
Journal of Crohn'S & Colitis|October 9, 2018
A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel DiseaseFabio Salvatore Macaluso, Walter Fries, Antonio Carlo Privitera, et al.
ESMO Open|June 15, 2024
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)E G Pizzutilo, A G Agostara, S Oresti, et al.
Tumori|May 4, 2026
Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to <i>KRAS</i> status: An Italian real-world studyAlessandro Leonetti, Vanessa Callegari, Fabiana Perrone, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2024
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexedAlessandro Leonetti, Fabiana Perrone, Matteo Puntoni, et al.
Pageof 12

Showing results (101-110 of 116) with videos related to

Sort By:
Pageof 12
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 27, 2018
The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseasesFabio Salvatore Macaluso, Rosalba Orlando, Walter Fries, et al.
Retina (Philadelphia, Pa.)|December 29, 2017
COLORADO AGE-RELATED MACULAR DEGENERATION REGISTRY: Design and Clinical Risk Factors of the CohortAnne M Lynch, Jennifer L Patnaik, Jennifer N Cathcart, et al.
United European Gastroenterology Journal|August 11, 2020
Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre studyFabio Salvatore Macaluso, Walter Fries, Sara Renna, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 16, 2018
A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysisSara Renna, Filippo Mocciaro, Marco Ventimiglia, et al.
Drugs & Aging|February 5, 2020
Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)Serena Porcari, Anna Viola, Ambrogio Orlando, et al.
Nature|March 23, 2010
Intense star formation within resolved compact regions in a galaxy at z = 2.3A M Swinbank, I Smail, S Longmore, et al.
Journal of Crohn'S & Colitis|October 9, 2018
A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel DiseaseFabio Salvatore Macaluso, Walter Fries, Antonio Carlo Privitera, et al.
ESMO Open|June 15, 2024
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)E G Pizzutilo, A G Agostara, S Oresti, et al.
Tumori|May 4, 2026
Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to <i>KRAS</i> status: An Italian real-world studyAlessandro Leonetti, Vanessa Callegari, Fabiana Perrone, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2024
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexedAlessandro Leonetti, Fabiana Perrone, Matteo Puntoni, et al.
Pageof 12